Enliven Therapeutics, Inc. Quarterly Assets, Current in USD from Q4 2019 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
Summary
Enliven Therapeutics, Inc. quarterly Assets, Current history and growth rate from Q4 2019 to Q4 2024.
  • Enliven Therapeutics, Inc. Assets, Current for the quarter ending December 31, 2024 was $318M, a 19.5% increase year-over-year.
Assets, Current, Quarterly (USD)
Assets, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2024 $318M +$52M +19.5% Dec 31, 2024 10-K 2025-03-13
Q3 2024 $297M +$28.4M +10.6% Sep 30, 2024 10-Q 2024-11-13
Q2 2024 $318M +$35M +12.3% Jun 30, 2024 10-Q 2024-08-13
Q1 2024 $337M +$39.2M +13.2% Mar 31, 2024 10-Q 2024-05-14
Q4 2023 $266M +$188M +242% Dec 31, 2023 10-K 2025-03-13
Q3 2023 $269M +$210M +354% Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $283M +$219M +341% Jun 30, 2023 10-Q 2023-08-10
Q1 2023 $298M +$219M +279% Mar 31, 2023 10-Q 2023-05-11
Q4 2022 $77.8M -$32.9M -29.7% Dec 31, 2022 10-K 2024-03-14
Q3 2022 $59.1M -$46.9M -44.2% Sep 30, 2022 10-Q 2022-10-25
Q2 2022 $64.3M -$7.1M -9.95% Jun 30, 2022 10-Q 2022-08-03
Q1 2022 $78.5M -$1.83M -2.28% Mar 31, 2022 10-Q 2022-05-06
Q4 2021 $111M +$20.3M +22.4% Dec 31, 2021 8-K 2023-06-23
Q3 2021 $106M +$6.29M +6.3% Sep 30, 2021 10-Q 2021-11-09
Q2 2021 $71.4M -$39.2M -35.5% Jun 30, 2021 10-Q 2021-08-06
Q1 2021 $80.4M -$29.5M -26.8% Mar 31, 2021 10-Q 2021-05-11
Q4 2020 $90.4M +$59.8M +195% Dec 31, 2020 10-K 2022-03-15
Q3 2020 $99.7M Sep 30, 2020 10-Q 2020-11-05
Q2 2020 $111M Jun 30, 2020 10-Q 2020-08-14
Q1 2020 $110M Mar 31, 2020 10-Q 2020-05-07
Q4 2019 $30.6M Dec 31, 2019 10-K 2021-03-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.